Page last updated: 2024-11-07

alpha-difluoromethyl-dopa

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alpha-difluoromethyl-DOPA: inhibitor of L-amino acid decarboxylase; RN given refers to (alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129677
SCHEMBL ID11574844
MeSH IDM0091620

Synonyms (23)

Synonym
dfm-dopa
69955-03-9
(2s)-2-amino-2-[(3,4-dihydroxyphenyl)methyl]-3,3-difluoropropanoic acid
alpha-difluoromethyl-3,4-dihydroxyphenylalanine
tyrosine, alpha-(difluoromethyl)-3-hydroxy-
mdl 71,801
alpha-difluoromethyl-dopa
alpha-(difluoromethyl)-3-hydroxytyrosine
DTXSID70220233
SCHEMBL11574844
alpha-(difluoromethyl)-3-hydroxy-l-tyrosine
l-tyrosine, alpha-(difluoromethyl)-3-hydroxy-
unii-4fx102brl6
.alpha.-difluoromethyl-dopa
160401-53-6
difluoromethyldopa
4FX102BRL6 ,
.alpha.-(difluoromethyl)-3-hydroxy-l-tyrosine
l-tyrosine, .alpha.-(difluoromethyl)-3-hydroxy-
difluoromethyldopa [who-dd]
dfmd
Q4734901
xzvhhlnllvicfa-snvbaglbsa-n

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" 163) on the serum t1/2 and other pharmacokinetic parameters of co-administered L-3,4-dihydroxyphenylalanine (L-DOPA) were compared to those of the reversible inhibitor, carbidopa in rats."( A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine.
Haegele, KD; Huebert, ND; Palfreyman, MG,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" 163, administered as their DL-racemic mixtures, produced increases in the t1/2 and bioavailability of co-administered L-DOPA comparable to that produced by a 10-fold larger dose of carbidopa administered as the active L-enantiomer; increasing the dose of MDL 72."( A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine.
Haegele, KD; Huebert, ND; Palfreyman, MG,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (50.00)18.7374
1990's2 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]